4588.T) announced">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 6, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Oncolys BioPharma Secures Unsecured Loan for OBP-301 Revenue

Source disclosure: February 06, 2026 Oncolys BioPharma Inc. [4588.T] TOKYO, Feb 06 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced today that its board of directors has approved a new unsecured loan agreement with Mizuho Bank Ltd. The loan amount is ¥4 billion and will commence in February 2026. The funds will partially repay revenue generated from the planned December 2026 launch of tumor-dissolving virus OBP-301. Key terms of the loan include: 1. Borrowing bank: Mizu

View all 4588.T disclosures →

Share this disclosure: Share on X Share on LinkedIn